Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Kuros Biosciences AG is a Switzerland-based biotechnology company specializing in the discovery, development, and commercialization of innovative biologic technologies for bone healing and regeneration. Headquartered in Schlieren, with operations in the Netherlands and the USA, it focuses on advanced medical devices like the MagnetOs family of synthetic bone grafts, including Granules, Putty, Flex Matrix, and Easypack Putty, which have received FDA clearances for standalone, interbody, extremities, and pelvis applications. The company transitioned from a legacy biotechnology portfolio to dominate in medical devices, with sales surging from 8.34 million CHF in 2021 to 75.56 million CHF in 2024, primarily driven by the US market at 72.84 million CHF. Employing 158 people, Kuros Biosciences AG advances orthopedics and spinal applications through rigorous clinical evidence, such as Level 1 studies published in Spine journal, and strategic partnerships like with Medtronic's spinal division. Led by CEO Christopher Fair since 2023, it plays a key role in the biotechnology and medical research sector by addressing unmet needs in bone grafting with high-quality, evidence-based solutions.
Operating margin is thin at 6.13%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 71.5% YoY with margins expanding 12.7pp. However, free cash flow softened 227%, worth monitoring whether this is timing or structural.
Free cash flow declined 227% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -CHF 3M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
CHF 146M
▲ +71.5% YoY
Net Income (TTM)
CHF 3M
▲ +152.8% YoY
Op. Margin
6.13%
▲ +12.7pp YoY
ROIC
5.88%
▲ +13.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-CHF 3M
▼ -226.5% YoY
Op. Cash Flow (TTM)
-CHF 455K
▼ -112.9% YoY
Net Debt
-CHF 18M
Net Cash Position
Cash & Equiv.
CHF 19M
3Y CAGR: +101.0%
Continue Research